How to buy GlaxoSmithKline (GSK) shares in Australia
Learn how to easily invest in GlaxoSmithKline shares.
GlaxoSmithKline PLC ADR is a drug manufacturers - general business with stocks listed in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$35.99 – an increase of 0.5% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in GlaxoSmithKline
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for GlaxoSmithKline. Find the share by name or ticker symbol: GSK. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GlaxoSmithKline reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$35.99, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of GlaxoSmithKline, depending on your broker.
- Check in on your investment. Congratulations, you own a part of GlaxoSmithKline. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
What's in this guide?
- GlaxoSmithKline key stats
- Compare share trading platforms
- Is GlaxoSmithKline stock a buy or sell?
- GlaxoSmithKline performance over time
- Are GlaxoSmithKline shares over-valued?
- GlaxoSmithKline's financials
- How volatile are GlaxoSmithKline shares?
- Does GlaxoSmithKline pay a dividend?
- Have GlaxoSmithKline shares ever split?
- Other common questions
GlaxoSmithKline stock price (NYSE:GSK)Use our graph to track the performance of GSK stocks over time.
Have GlaxoSmithKline's shares ever split?
GlaxoSmithKline's shares were split on a 1226:1000 basis on 22 July 2022. So if you had owned 1000 shares the day before the split, the next day you would own 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
GlaxoSmithKline shares at a glance
|52-week range||US$32.2211 - US$38.1993|
|50-day moving average||US$35.954|
|200-day moving average||US$35.5065|
|Dividend yield||US$0.558 (3.91%)|
|Earnings per share (TTM)||US$3.71|
GlaxoSmithKline price performance over time
|1 week (2023-11-24)||0.50%|
|1 month (2023-11-02)||5.33%|
|3 months (2023-09-01)||2.74%|
|6 months (2023-06-02)||5.51%|
|1 year (2022-12-02)||1.81%|
|2 years (2021-12-02)||6.40%|
|3 years (2020-12-02)||17.98%|
|5 years (2018-11-30)||5.38%|
Compare trading platforms to buy GlaxoSmithKline shares
Is it a good time to buy GlaxoSmithKline stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is GlaxoSmithKline under- or over-valued?
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's P/E ratio
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, GlaxoSmithKline shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's PEG ratio
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1245. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9.2 billion (£7.2 billion).
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
GlaxoSmithKline share price volatility
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as US$32.2211 up to US$38.1993. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.289. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
|Revenue TTM||US$29.7 billion|
|Operating margin TTM||31.37%|
|Gross profit TTM||US$19.9 billion|
|Return on assets TTM||7.9%|
|Return on equity TTM||61.26%|
|Market capitalisation||US$73.3 billion|
TTM: trailing 12 months
GlaxoSmithKline share dividends
Dividend payout ratio: 36.98% of net profits
Recently GlaxoSmithKline has paid out, on average, around 36.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.91% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 3.91% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.558 per share.
While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.
GlaxoSmithKline's most recent dividend payout was on 11 January 2024. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2023 (the "ex-dividend date").
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Stocks similar to GlaxoSmithKline
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert